子宫肌瘤 中国就医指南

Uterine leiomyoma—commonly known as uterine fibroids—is a benign monoclonal smooth muscle tumor arising from the myometrium of the uterus. These tumors are estrogen- and progesterone-sensitive, exhibiting growth during reproductive years and typically regressing after menopause. Pathogenically, leiomyomas originate from genetic alterations in myometrial stem cells, with recurrent mutations in the MED12 gene (present in ~70% of cases), HMGA2 rearrangements, and abnormalities in the TGF-β, WNT/β-catenin, and PI3K/AKT/mTOR signaling pathways. Epigenetic dysregulation, extracellular matrix remodeling, and local tissue hypoxia further contribute to tumor initiation and expansion. Epidemiologically, uterine leiomyomas affect approximately 40–80% of women by age 50, with higher prevalence among Black women (up to 80% by age 45), earlier onset, larger size, and greater symptom burden. Risk factors include early menarche (<11 years), nulliparity, obesity (BMI ≥30), hypertension, vitamin D deficiency, family history, and African ancestry. Conversely, parity, oral contraceptive use (especially long-term low-dose formulations), and smoking (though not recommended due to health risks) are associated with reduced risk. Symptomatology varies widely: up to 50% of cases are asymptomatic, while others experience heavy or prolonged menstrual bleeding (menorrhagia), pelvic pressure or pain, urinary frequency or retention, constipation, dyspareunia, and reproductive challenges—including subfertility, recurrent pregnancy loss, and obstetric complications such as placental abruption or preterm birth. Quality of life impact is substantial: chronic anemia from blood loss leads to fatigue and cognitive impairment; pelvic discomfort restricts physical activity and sexual function; and emotional distress—including anxiety, depression, and diminished body image—is prevalent, particularly among younger patients facing fertility concerns. Economic burden extends beyond direct medical costs to lost work productivity and caregiver strain. Early diagnosis via transvaginal ultrasound (TVUS) or MRI is critical for risk stratification and personalized management. Given its hormone-dependent nature and heterogeneous clinical behavior, treatment must be individualized—not solely based on size or number, but on symptom severity, reproductive goals, patient preference, and anatomical location (submucosal, intramural, subserosal, or pedunculated). Multidisciplinary care involving reproductive endocrinologists, interventional radiologists, gynecologic oncologists, and minimally invasive surgeons ensures optimal outcomes in the Department of Reproductive Medicine.

# 子宫肌瘤治疗方案与费用明细（生殖医学科）

一、非手术保守治疗

适用人群：无症状小肌瘤（＜5 cm）、围绝经期、有生育需求者

• •药物治疗：

- 米非司酮（短期控制）：1,800–3,500元/3个月（含肝功、子宫内膜活检） - 中药周期调理（三甲医院院内制剂）：2,400–4,200元/3个月

• •检查费：盆腔超声（三维）280–420元；MRI平扫（必要时）720–980元

二、手术与介入治疗

适用人群：肌瘤≥5 cm、压迫症状、不孕、黏膜下肌瘤或药物无效者

• •宫腔镜肌瘤切除术（黏膜下为主）：12,500–18,600元（含术前宫颈预处理、麻醉、病理）
• •腹腔镜肌瘤剔除术（浆膜下/肌壁间）：16,800–24,300元（含术中冰冻、术后激素管理）
• •高强度聚焦超声（HIFU）消融：15,000–21,000元（单次，需符合肌瘤位置及血供条件）
• •术前检查包（必查）：2,100–3,400元（含心电图、凝血四项、传染病筛查、盆腔增强MRI）

三、特殊复杂情况

• •多发性巨大肌瘤（≥8 cm×3枚以上）或合并腺肌病：个体化联合方案，28,000–45,000元（含多学科会诊、术中输血备用、术后康复管理）
• •耐药性肌瘤（GnRH-a抵抗）：加用新型选择性孕酮受体调节剂（如乌利普利司），8,500–12,000元/6个月

四、方案快速选择指南

✅ 预算有限+有生育需求 → 宫腔镜切除（首选） ✅ 无生育要求+追求根治 → 腹腔镜剔除+术后GnRH-a巩固 ✅ 拒绝手术+肌瘤＜4 cm → 米非司酮+定期超声随访（年均检查费≤1,200元） ✅ 高龄围绝经期+多发小肌瘤 → 观察+中药调理（年均总费用≤4,500元）